ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2019
Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- Impact of a Multifaceted Antimicrobial Stewardship Program on Antimicrobial Use and Prescription Quality in a Pediatric Intensive Care Unit: An Interrupted Time-Series Study.Antibiotics (Basel, Switzerland) · 2026Article
- The impact of faster antimicrobial susceptibility testing report and dual antimicrobial susceptibility testing cards on the antibiotic therapy and economics of hospitalized bloodstream infection patients.BMC microbiology · 2026Article
- Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review.JAC-antimicrobial resistance · 2025Review
- Observational
- Implementing antimicrobial stewardship: lessons and perspectives from a university-affiliated tertiary hospital in Korea.The Korean journal of internal medicine · 2024Article
- New Approaches to Overcoming Antimicrobial Resistance in Endophthalmitis.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Multidrug-Resistant Sepsis: A Critical Healthcare Challenge.Antibiotics (Basel, Switzerland) · 2024Review
- Assessing the rationale of prescribing carbapenems among hospitalized patients with documented penicillin allergy: implications for stewardship.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- A carbapenem-focused antimicrobial stewardship programme implemented during the COVID-19 pandemic in a setting of high endemicity for multidrug-resistant Gram-negative bacteria.The Journal of antimicrobial chemotherapy · 2023Article
- Impact of an antibiotic stewardship program on antibiotic utilization, bacterial susceptibilities, and cost of antibiotics.Scientific reports · 2023Article
- Practical Concerns about the Metrics and Methods of Financial Outcome Measurement in Antimicrobial Stewardship Programs: A Narrative Review.Iranian journal of medical sciences · 2022Review
- Antimicrobial Stewardship Improvement in Pediatric Intensive Care Units in Spain-What Have We Learned?Children (Basel, Switzerland) · 2022Article
- Emerging antimicrobial resistance and need for antimicrobial stewardship for ocular infections in India: A narrative review.Indian journal of ophthalmology · 2022Review
- Antimicrobial Stewardship Programs: A Review of Strategies to Avoid Polymyxins and Carbapenems Misuse in Low Middle-Income Countries.Antibiotics (Basel, Switzerland) · 2022Review
- Impact of the Acceptance of the Recommendations Made by a Meropenem Stewardship Program in a University Hospital: A Pilot Study.Antibiotics (Basel, Switzerland) · 2022Article
- Antibiotic-resistant bacteria: COVID-19 hasn't made the challenge go away.Respirology (Carlton, Vic.) · 2021Article
- Guidelines on Implementing Antimicrobial Stewardship Programs in Korea.Infection & chemotherapy · 2021Review
- Impact of an Antimicrobial Stewardship Program on the Incidence of Carbapenem Resistant Gram-Negative Bacilli: An Interrupted Time-Series Analysis.Antibiotics (Basel, Switzerland) · 2021Article
- Article
- Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan.Journal of health economics and outcomes research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are few prospective studies with sufficient duration in time to evaluate clinical and antibiotic resistance impact of antibiotic stewardship programs (ASP). This is a descriptive study between January 2012 and December 2017, pre-post intervention. A meropenem ASP was initiated in January 2015; in patients who started treatment with meropenem, an infectious disease physician performed treatment recommendations to prescribers. Prospective information was collected to evaluate adequacy of meropenem prescription to local guidelines and to compare results between cases with accepted or rejected intervention. Analysis was performed to verify variables associated with intervention acceptance and with any significant change in meropenem consumption, hospital-acquired multidrug-resistant (MDR) bloodstream infections (BSIs), and 30-day all-cause crude death in MDR BSIs. Adequacy of meropenem prescription and de-escalation from meropenem treatment to narrower-spectrum antibiotic improved progressively over time, after ASP implementation (p < 0.001). Interventions on prescription were performed in 330 (38.7%) patients without meropenem justified treatment; in 269, intervention was accepted and in 61 not. Intervention acceptance was associated with shorter duration of treatment, cost, and inpatient days (p < 0.05); intervention rejection was not associated with severity of patient. During the period 2015-2017, meropenem consumption decreased compared with 2012-2014 (rate ratio [RR] 0.67; 95% CI 0.58-0.77, p < 0.001). Also decreased were hospital-acquired MDR BSI rate (RR 0.63; 95% CI 0.38-1.02, p = 0,048) and 30-day all-cause crude death in MDR BSIs (RR 0.45; 95% CI 0.14-1.24, p = 0.096), coinciding in time with ASP start-up. The decrease and better use of meropenem achieved had a sustained clinical, economic, and ecological impact, reducing costs and mortality of hospital-acquired MDR BSIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.